PhaseBio Pharmaceuticals Inc expected to post a loss of 46 cents a share - Earnings Preview

PhaseBio Pharmaceuticals

07/08/2021 01:47

* PhaseBio Pharmaceuticals Inc  PHAS.OQ   PHAS.O  is expected
to show a rise in quarterly revenue when it reports results on
August 9 (estimated). 
* The Malvern, Pennsylvania-based company is expected to report
revenue of $5.02 million, according to the mean estimate from 4
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for PhaseBio
Pharmaceuticals Inc is for a loss of 46 cents per share. For the
same quarter last year, the company reported a loss of 98 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for PhaseBio
Pharmaceuticals Inc is $16.5​, about 79.6% above​ its last
closing price of $3.37. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.73       -0.73      -0.87     Missed  -18.6
 Dec. 31 2020  -0.67       -0.70      -1.03     Missed  -46.1
 Sep. 30 2020  -0.78       -0.77      -0.86     Missed  -12.1​
 Jun. 30 2020  -0.53       -0.52      -0.98     Missed  -88.5
 Mar.          -0.37​      -0.37      -0.52     Missed  -42.3​
 31​ 2020​                                              
 Dec. 31 2019  -0.37       -0.40      -0.39     Beat    2.8​
 Sep. 30 2019  -0.37       -0.37      -0.40     Missed  -8.7
 Jun. 30 2019  -0.32       -0.32      -0.33     Missed  -3.4
 This summary was machine generated August 7 at 00:47 GMT.  All
figures in US dollars unless otherwise stated